Phase 1 Trial Evaluating the Safety and Tolerability of Gamma Delta T-Cell Infusions in Combination with Low Dose Radiotherapy in Subjects with Locally Advanced or Metastatic Non-Small Cell Lung Cancer or Solid Tumors with Bone Metastases
Latest Information Update: 10 Mar 2025
At a glance
- Drugs Gamma delta chimeric antigen receptor T-cell therapy-Kiromic (Primary)
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions; First in man
- Acronyms Deltacel-01
- Sponsors Kiromic
Most Recent Events
- 05 Mar 2025 Planned End Date changed from 1 Jan 2027 to 1 Oct 2026.
- 05 Mar 2025 Planned primary completion date changed from 1 Oct 2024 to 1 Oct 2025.
- 18 Feb 2025 According to a Kiromic media release, Kiromic reports that two subjects are undergoing screening and are scheduled to start treatment at Texas Oncology in Tyler, Texas, in late February and early March, respectively